ALKERMES | ALKS - Selling And Administration Expenses


ALKERMES reported $196.64M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Amgen USD 1.72B 134M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.43B 496M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
J&J USD 6.42B 381M Jun/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 2.89B 219M Jun/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Otsuka Holdings JPY 274.44B 14.95B Jun/2026
Ovoca Bio EUR 617K 15K Dec/2025
Pfizer USD 3.41B 496M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026